These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14659814)

  • 61. Clinical and pathological characteristics of homogeneous and nonhomogeneous tissue of in-stent restenosis visualized by optical coherence tomography.
    Itoh T; Fusazaki T; Kimura T; Oikawa H; Sasou S; Ishikawa Y; Goto I; Komuro K; Nakajima S; Koeda Y; Kaneko K; Nishiyama O; Nakamura M; Morino Y
    Coron Artery Dis; 2015 May; 26(3):201-11. PubMed ID: 25714072
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
    Katayama T; Ueba H; Tsuboi K; Kubo N; Yasu T; Kuroki M; Saito M; Momomura S; Kawakami M
    Am Heart J; 2007 May; 153(5):762.e1-7. PubMed ID: 17452150
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Does a carbon ion-implanted surface reduce the restenosis rate of coronary stents?
    Jung JH; Min PK; Kim JY; Park S; Choi EY; Ko YG; Choi D; Jang Y; Shim WH; Cho SY
    Cardiology; 2005; 104(2):72-5. PubMed ID: 16020923
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. Tissue characteristics compared to primary atherosclerosis.
    Skowasch D; Jabs A; Andrié R; Dinkelbach S; Schiele TM; Wernert N; Lüderitz B; Bauriedel G
    J Vasc Res; 2004; 41(6):525-34. PubMed ID: 15528935
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.
    Kotani J; Awata M; Nanto S; Uematsu M; Oshima F; Minamiguchi H; Mintz GS; Nagata S
    J Am Coll Cardiol; 2006 May; 47(10):2108-11. PubMed ID: 16697331
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of plaque debulking before stent implantation on in-stent neointimal proliferation: a serial 3-dimensional intravascular ultrasound study.
    Takeda Y; Tsuchikane E; Kobayashi T; Terai K; Kobayashi Y; Nakagawa T; Sakurai M; Awata N; Kobayashi T
    Am Heart J; 2003 Jul; 146(1):175-82. PubMed ID: 12851628
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Heterogeneity of neointimal distribution of in-stent restenosis in patients with diabetes mellitus.
    Kaneda H; Ako J; Kataoka T; Takahashi T; Terashima M; Waseda K; Miyazawa A; Hassan A; Honda Y; Yock PG; Fitzgerald PJ
    Am J Cardiol; 2006 Feb; 97(3):340-2. PubMed ID: 16442392
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease.
    Wöhrle J; Birkemeyer R; Markovic S; Nguyen TV; Sinha A; Miljak T; Spiess J; Rottbauer W; Rittger H
    Heart; 2011 Aug; 97(16):1338-42. PubMed ID: 21617163
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.
    Chevalier B; Di Mario C; Neumann FJ; Ribichini F; Urban P; Popma JJ; Fitzgerald PJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Schwartz LB;
    JACC Cardiovasc Interv; 2008 Oct; 1(5):524-32. PubMed ID: 19463354
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first.
    Gutiérrez-Chico JL; van Geuns RJ; Koch KT; Koolen JJ; Duckers H; Regar E; Serruys PW
    EuroIntervention; 2011 Oct; 7(6):711-22. PubMed ID: 21986329
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies.
    Ohsawa H; Noike H; Kanai M; Hitsumoto T; Aoyagi K; Sakurai T; Sugiyama Y; Yoshinaga K; Kaku M; Matsumoto J; Iizuka T; Shimizu K; Takahashi M; Tomaru T; Sakuragawa H; Tokuhiro K
    J Cardiol; 2003 Jul; 42(1):13-22. PubMed ID: 12892037
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Paclitaxcel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study.
    Fischer D; Scheller B; Schäfer A; Klein G; Böhm M; Clever Y; Cremers B
    EuroIntervention; 2012 Aug; 8(4):450-5. PubMed ID: 22917728
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Insertion of self-expandable nitinol stents without previous balloon angioplasty reduces restenosis compared with PTA prior to stenting.
    Harnek J; Zoucas E; Stenram U; Cwikiel W
    Cardiovasc Intervent Radiol; 2002; 25(5):430-6. PubMed ID: 12042993
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
    Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P
    Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of Serum HMGB2 Levels With In-Stent Restenosis: HMGB2 Promotes Neointimal Hyperplasia in Mice With Femoral Artery Injury and Proliferation and Migration of VSMCs.
    He YH; Wang XQ; Zhang J; Liu ZH; Pan WQ; Shen Y; Zhu ZB; Wang LJ; Yan XX; Yang K; Zhang RY; Shen WF; Ding FH; Lu L
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):717-729. PubMed ID: 28183701
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optical coherence tomography evaluation of in-stent restenotic lesions with visible microvessels.
    Kim BK; Kim JS; Shin DH; Ko YG; Choi D; Jang Y; Hong MK
    J Invasive Cardiol; 2012 Mar; 24(3):116-20. PubMed ID: 22388303
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
    Kufner S; Joner M; Schneider S; Tölg R; Zrenner B; Repp J; Starkmann A; Xhepa E; Ibrahim T; Cassese S; Fusaro M; Ott I; Hengstenberg C; Schunkert H; Abdel-Wahab M; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2017 Jul; 10(13):1332-1340. PubMed ID: 28683939
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Local delivery of nadroparin for the prevention of neointimal hyperplasia following stent implantation: results of the IMPRESS trial. A multicentre, randomized, clinical, angiographic and intravascular ultrasound study.
    Meneveau N; Schiele F; Grollier G; Farah B; Lablanche JM; Khalifé K; Machecourt J; Danchin N; Wolf JE; Simpson M; Hak JB; Bassand JP
    Eur Heart J; 2000 Nov; 21(21):1767-75. PubMed ID: 11052841
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries.
    Wagenaar LJ; van Boven AJ; van der Wal AC; Amoroso G; Tio RA; van der Loos CM; Becker AE; van Gilst WH
    Cardiovasc Res; 2003 Oct; 59(4):980-7. PubMed ID: 14553838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.